Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.

Nature communications·2026

Same author

Compound Heterozygous Variants in the Phospholipase Gene PNPLA6 Cause Hypopituitarism and Vision Loss.

Human mutation·2026

Same author

Advancing Cancer Research in Resource-Limited Settings: Perspectives from Emerging Voices across Continents.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Role of the cross-regulation between Wnt pathway activation and androgen receptor signaling in prostate cancer treatment resistance.

Cell death and differentiation·2026

Same author

Updated compendium of genes and variants associated with congenital hypogonadotropic hypogonadism: systematic review, classification pipeline, and network analysis.

Human molecular genetics·2026

Same author

2025 Annual Meeting of Bioscience Societies SAIC - AAFE.

Medicina·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts

Agustina Sabater^1,2,3, Pablo Sanchis^1,2,3, Rocio Seniuk^1,2

¹Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina.

Medrxiv : the Preprint Server for Health Sciences

|October 14, 2024

Summary

This summary is machine-generated.

A new 7-gene signature predicts aggressive prostate cancer (PCa) and neuroendocrine prostate cancer (NEPC) progression. This tool aids personalized medicine by identifying high-risk patients for tailored treatment strategies.

Keywords:

Gene signature Large Cell Neuroendocrine Carcinoma Machine Learning Neuroendocrine Transdifferentiation Prognosis Prostate Cancer Stemness

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Area of Science:

Oncology
Genomics
Biomarkers

Background:

Prostate cancer (PCa) is a major global health concern.
Progression to aggressive neuroendocrine prostate cancer (NEPC) presents significant challenges.

Purpose of the Study:

Develop and validate a stemness-associated gene signature for PCa.
Identify patients with poor prognosis and NEPC subtypes.

Main Methods:

Utilized Random Forest and Lasso regression on large-scale transcriptomic data.
Validated a 7-gene signature (KMT5C, MEN1, TYMS, IRF5, DNMT3B, CDC25B, DPP4) in independent cohorts and xenograft models.

Main Results:

The 7-gene signature showed strong prognostic value for multiple survival endpoints.
Successfully identified NEPC subtypes and predicted poor outcomes in non-NEPC PCa with the signature.
Demonstrated dual prognostic and classifier capabilities.

Conclusions:

The validated 7-gene signature is a robust tool for personalized PCa management.
Enables prediction of disease progression and guides treatment strategies.
Offers valuable insights for identifying high-risk PCa patients.